Showing 1–25 of 29 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Wenping Gong, Jianping Xie, Hao Li, Ashok Aspatwar
…/tuberculosis). However, it is reported that the protective efficacy of BCG is highly variable and ranges between 0% and 80%, and its protection lasts only for 10 to 15 years [2]. Therefore, developing a new effective TB vaccine is pressing and challenging for governments and sci…
Wilkie MEM
…means there is a desperate need for a safe and effective TB vaccine. BCG is the only licensed vaccine and extremely variable in efficacy. However, BCG potentially exerts a non-specific beneficial effect - protecting infants from other causes of death such as respiratory infection…
Rakshit S, Adiga V, Ahmed A, Parthiban C, Chetan Kumar N, et al.
This proof-of-concept study tested if prior BCG revaccination can qualitatively and quantitively enhance antibody and T-cell responses induced by Oxford/AstraZeneca ChAdOx1nCoV-19 or COVISHIELD™, an efficacious and the most widely distributed vaccine in India. We compared COVISHI…
Yun Xu, Xiaochun Wang, Qiangsen Zhong
Bacillus Calmette-Guérin (BCG) is the only vaccine currently used in clinical practice to prevent tuberculosis (TB), however, it remains limited in preventing latent infection, TB reactivation, and providing comprehensive protection. In this study, the pcaA gene, an antigen …
Chen Z, Zhang Y, Wu J, Xu J, Hu Z, et al.
…remains a global challenge. Despite being the only licensed vaccine, Bacillus Calmette-Guérin (BCG) confers limited protective efficacy in adults and individuals with latent tuberculosis infections (LTBI). There is an urgent need to develop novel vaccines that can enhance the pro…
Wu Y, Cai M, Ma J, Teng X, Tian M, et al.
Adults are the leading population affected by tuberculosis (TB) epidemic and death. Developing an effective vaccine against adult TB is urgently needed. Mycobacterium bovis Bacillus Calmette-Guerin (BCG) prime-heterologous boost strategy has been explored extensively to protect a…
Mao LR, Du JP, Wang XC, Xu LF, Zhang YP, et al.
…dormant Mycobacterium tuberculosis is an important cause of adult tuberculosis (TB) transmission. According to the interaction mechanism between M. tuberculosis and the host, the latency antigen Rv0572c and region of difference 9 (RD9) antigen Rv3621c were selected in this study …
Wenping Gong, Ashok Aspatwar, Jianping Xie, Hao Li
…24, demands urgent innovation [1]. The limited and variable efficacy (0-80%) of the Bacille Calmette-Guérin (BCG) vaccine in adults, a challenge starkly highlighted during the COVID-19 pandemic, underscores the critical need for novel prophylactic and therapeutic strategies [2][3…
Zhao HM, Du R, Li CL, Ji P, Li HC, et al.
…s of Mtb-infected populations or development of therapeutic vaccines against tuberculosis (TB). Among them, Rv2028c is a dormancy-related antigen that has demonstrated potential use in TB control, but its immunological characteristics in the BCG-vaccinated Chinese population are …
Julio HR Croda, PhD
…ncarceration (on average 3 years), primary prophylaxis with BCG revaccination may be a cost-effective alternative associated with mass screening for control of the disease. Recently, in a phase 2 clinical trial, the BCG vaccine was shown to be 45% effective in preventing sustaine…
Fu H, Lin HH, Hallett TB, Arinaminpathy N
Background Bacillus Calmette-Guérin (BCG) vaccination is a widely-used public health intervention for tuberculosis (TB) control. In Taiwan, like other intermediate TB burden settings, steadily declining TB incidence raises important questions on whether universal BCG vaccination …
Gopalaswamy R, Subbian S
…se and the dose and nature of infecting bacilli. Currently, BCG is the only vaccine approved to prevent TB. Although BCG confers protection against severe forms of childhood TB, its use in adults and those with comorbid conditions, such as HIV infection, is questionable. Novel va…
Whitlow E, Mustafa AS, Hanif SNM
Currently, there is only one licensed vaccine against tuberculosis (TB), the Bacillus Calmette-Guérin (BCG). Despite its protective efficacy against TB in children, BCG has failed to protect adults against pulmonary TB, lacks therapeutic value, and causes complications in immunoc…
Mohamed E. El Zowalaty, Hossam M. Ashour
…emely drug-resistant Mtb. In addition, the only approved TB vaccine is the current vaccine Bacille Calmette-Guérin (BCG), which provides partial and variable protection. Currently, there are at least 16 candidate vaccines in various stages of clinical development in the global TB…
Wilson L, Gracie L, Kidy F, Thomas GN, Nirantharakumar K, et al.
…rring in low- and middle-income countries (LMICs). The only vaccine licenced for the prevention of TB has limited protection for adolescents, adults and vulnerable populations. A safe and effective vaccine for all populations at risk is imperative to achieve global elimination of…
Xiaofang Zhao, Caihong Guo, Lianwen Wang, Zhijun Liu
…merge in the absence of systematic interventions. While the BCG vaccine provides substantial protection against infantile TB, its efficacy against pulmonary TB in adults varies significantly. Currently, six candidate vaccines aimed at preventing or delaying the progression from L…
Buyun Xu, Mengjuan Yuan, Lisa Yang, Lan Huang, Jingxin Li, et al.
…erculosis (MTB), is one of the leading infectious causes of adult mortality worldwide. The Bacillus Calmette-Guérin (BCG) vaccine is currently the only approved vaccine for TB prevention, but its protective efficacy against adult pulmonary TB is limited, and it lacks effecti…
Naqvi N, Ahuja Y, Zarin S, Alam A, Ali W, et al.
The BCG vaccine represents a significant milestone in the prevention of tuberculosis (TB), particularly in children. Researchers have been developing recombinant BCG (rBCG) variants that can trigger lasting memory responses, thereby enhancing protection against TB in adults. The …
Sethi G, Varghese RP, Lakra AK, Nayak SS, Krishna R, et al.
…the situation more concerning. Currently, the only licensed vaccine BCG (Bacillus Calmette-Guérin) is ineffective in preventing adult pulmonary tuberculosis prophylaxis and latent tuberculosis re-activation. Therefore, there is a pressing need to find novel and safe vaccines that…
Lubyayi L, Mawa PA, Nabakooza G, Nakibuule M, Tushabe JV, et al.
Background: BCG has low efficacy in tropical countries. We hypothesized that maternal latent Mycobacterium tuberculosis (M.tb) infection (LTBI) results in fetal tolerance to mycobacterial antigens and impaired responses to BCG immunization. Methods: We enrolled 132 LTBI-positive …
Jessica R Jarvela, Julie G Burel, Michelle Moyer, Bonnie A Thiel, Htin Aung, et al.
…ldwide public health threat, in part because of the limited efficacy of current BCG vaccination. Respiratory infection with Mycobacterium tuberculosis (Mtb) is most often followed by the development of protective immunity that contains the pathogen, resulting in latent tuberculos…
Yadav J, Phogat S, Chaudhary D, Jaiwal R, Jaiwal PK
Objectives The only approved vaccine, Bacillus Calmette Guérin (BCG) used in global tuberculosis (TB) immunization programmes has been very effective in childhood TB but not in adult pulmonary and latent TB. Moreover, the emergence of multi-drug resistance-TB cases demands either…
Qiangsen Zhong, Xiaochun Wang, Yun Xu, Runlin Wang, Mingming Zhou, et al.
…, Rv3334, and Rv3406) in LTBI and evaluated the immunologic efficacy of a novel subunit vaccine, PB2-DIMQ (antigen PB2:Rv0470c-Rv1846c; adjuvant DIMQ: liposome dimethyl dioctadecylammonium bromide [DDA] + imiquimod [IMQ]). It was found that all five antigens were genera…
Jann-Yuan Wang, Ph.D.
… investigators designed this prospective study to follow up adult household contacts with LTBI for 2 years and compare the efficacy of 9-month isoniazid and 4-month rifampicin). In countries with a low incidence of tuberculosis (TB), most new, active cases have occurred among pe…
Strong EJ, West NP
The current vaccine for tuberculosis (TB) is a live attenuated strain of Mycobacterium bovis (BCG) and while effective at reducing the potential for disseminated TB in young children its disease protection rates in adults is highly variable while it confers little protection agai…